Home > PE Ratio > NATCO PHARMA

NATCO PHARMA
PE (Price/Earnings) Ratio

The Current P/E Ratio of NATCO PHARMA is 12.76.

Share Price ₹1,385.4Jan 02,2025
Market Cap ₹24,811.6 Cr
Earnings-TTM₹1,944.0 CrTTM-Consolidated Results
Price/Earnings12.76xCalculated as Market Cap/Earnings
Explore Stock Analytics
COMMUNITY POLL
for NATCO PHARMA
Please provide your vote to see the results
NATCO PHARMA is part of below Screeners ↓
Top Undervalued Small Cap Stocks
Best Quarterly Growth Small Cap Stocks

Definition & Calculation of PE (Price/Earnings) ratio of NATCO PHARMA

Price-to-Earnings ratio, P/E Multiple, or P/E Ratio is an important valuation multiple that is defined as:

P/E = Market Capitalization / Net Income

or, using per-share numbers:

P/E = Stock Price / Earnings Per Share (EPS)

Applying the above formula, P/E ratio of NATCO PHARMA is calculated as :

Current Market Cap [ ₹24,811.6 Cr] as on Jan 02,2025

(/) Earnings [ ₹1,944.0 Cr] based on TTM-Consolidated Results

(=) P/E Ratio [ 12.76x ]

P/E Ratio indicates the multiple of earnings investors are willing to pay to own one share of the company.

Thus, for NATCO PHARMA , the investors are currently willing to pay 12.76 times earnings to own 1 share of the company.

PE Multiples are the most widely used valuation multiple in practice.

Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.

In such cases, you may consider using Price to Book ratio or Price to Sales ratio of NATCO PHARMA !

P/E ratios, also, would not adjust for differences in the capital structure between companies.

The chart below summarizes the trend in P/E Ratio of NATCO PHARMA over the last five years.

Historical PE (Price/Earnings) ratio chart of NATCO PHARMA


PE Ratio Performance Analysis for NATCO PHARMA

- NATCO PHARMA 's latest p/e ratio is 12.76x.

- NATCO PHARMA 's p/e ratio for fiscal years ending Mar2024 to Mar2020 averaged 32.42x.

- NATCO PHARMA 's operated at median p/e ratio of 19.99x from fiscal years ending March 2018 to 2022.

- Looking back at the last 5 fiscal years, NATCO PHARMA 's p/e ratio peaked in Mar2022 at 81.3x.

- NATCO PHARMA 's p/e ratio hit its five-year low in Mar2024 of 12.27x.


How does NATCO PHARMA 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?

Peer Comparison (Pharmaceuticals & Drugs Industry)Earnings-TTM (Cr)PE RatioMarket Cap
NATCO PHARMA 1,944.0012.7624,811.6
SUN PHARMACEUTICAL INDUSTRIES LTD11,136.5040.46450,595.0
CIPLA LTD4,485.2227.69124,175.0
DR REDDYS LABORATORIES LTD5,406.8021.20114,625.0
ZYDUS LIFESCIENCES LTD4,298.9023.1999,672.5
DIVIS LABORATORIES LTD1,836.0088.83163,089.0
MANKIND PHARMA LTD2,124.8656.30119,626.0
TORRENT PHARMACEUTICALS LTD1,802.0064.73116,637.0
LUPIN LTD2,651.9441.23109,327.0
AUROBINDO PHARMA LTD3,598.8321.7778,329.8
ABBOTT INDIA LTD1,284.6649.5363,622.8

Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs NATCO PHARMA 's P/E Ratio

Top 10 Industry PeersPE Ratio
Min industry PE 12.76x
Max industry PE 88.83x
Median industry PE 40.46x
Average industry PE 40.70x



You may also like the below Video Courses